Bendroflumethiazide

Jump to: navigation, search
Bendroflumethiazide
Bendroflumethiazide-3D-vdW.png
Clinical data
AHFS/Drugs.comConsumer Drug Information
Pregnancy
category
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability100%
Protein binding96%
Metabolismextensive
Elimination half-life3-4 hours[2]
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H14F3N3O4S2
Molar mass421.415 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Bendroflumethiazide

Articles

Most recent articles on Bendroflumethiazide

Most cited articles on Bendroflumethiazide

Review articles on Bendroflumethiazide

Articles on Bendroflumethiazide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bendroflumethiazide

Images of Bendroflumethiazide

Photos of Bendroflumethiazide

Podcasts & MP3s on Bendroflumethiazide

Videos on Bendroflumethiazide

Evidence Based Medicine

Cochrane Collaboration on Bendroflumethiazide

Bandolier on Bendroflumethiazide

TRIP on Bendroflumethiazide

Clinical Trials

Ongoing Trials on Bendroflumethiazide at Clinical Trials.gov

Trial results on Bendroflumethiazide

Clinical Trials on Bendroflumethiazide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bendroflumethiazide

NICE Guidance on Bendroflumethiazide

NHS PRODIGY Guidance

FDA on Bendroflumethiazide

CDC on Bendroflumethiazide

Books

Books on Bendroflumethiazide

News

Bendroflumethiazide in the news

Be alerted to news on Bendroflumethiazide

News trends on Bendroflumethiazide

Commentary

Blogs on Bendroflumethiazide

Definitions

Definitions of Bendroflumethiazide

Patient Resources / Community

Patient resources on Bendroflumethiazide

Discussion groups on Bendroflumethiazide

Patient Handouts on Bendroflumethiazide

Directions to Hospitals Treating Bendroflumethiazide

Risk calculators and risk factors for Bendroflumethiazide

Healthcare Provider Resources

Symptoms of Bendroflumethiazide

Causes & Risk Factors for Bendroflumethiazide

Diagnostic studies for Bendroflumethiazide

Treatment of Bendroflumethiazide

Continuing Medical Education (CME)

CME Programs on Bendroflumethiazide

International

Bendroflumethiazide en Espanol

Bendroflumethiazide en Francais

Business

Bendroflumethiazide in the Marketplace

Patents on Bendroflumethiazide

Experimental / Informatics

List of terms related to Bendroflumethiazide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bendroflumethiazide (INN), formerly bendrofluazide (BAN), trade name Aprinox, is a thiazide diuretic used to treat hypertension.

Bendroflumethiazide is a thiazide diuretic which works by inhibiting sodium reabsorption at the beginning of the distal convoluted tubule (DCT). Water is lost as a result of more sodium reaching the collecting ducts. Bendroflumethiazide has a role in the treatment of mild heart failure although loop diuretics are better for reducing overload. The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to vasodilation).

Common adverse effects:

Rare adverse effects:

References

  1. BNF 45 March 2003
  2. Ed. Sean C. Sweetman (ed.). Martindale: The complete drug reference (33 ed.). Pharmaceutical Press.

Linked-in.jpg